A complex process that Congress will use to vote on the health reform bill might lead to the exclusion of a proposal to ban pay-for-delay deals between brand-name and generic-drug firms. Sen. Herb Kohl, D-Wis., intends to push the provision later if it gets dropped from the overhaul legislation, a spokeswoman said.

Related Summaries